Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., operating under Nasdaq-listed ticker DECA, filed an 8-K on April 12, 2023, disclosing material corporate developments related to its de-SPAC transaction. DECA is Decathlon Alpha IV Acquisition Corp, a healthcare-focused special purpose acquisition company that completed its initial public offering in 2021 and is sponsored by Decathlon Alpha Management, LLC. Semnur is a clinical-stage specialty pharmaceutical company developing non-opioid therapies targeting spine-related pain conditions. The April 2023 filing reflects ongoing disclosure obligations as the proposed business combination progressed through regulatory and shareholder processes. For complete filing history, deal timelines, and SPAC analytics on DECA, sign up for full data access at SpacDesk.